Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03024684 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Study acronym: SHOT
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 12, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 6 of 6 sites
    v7
  2. Primary completion date: Jan 2022 to Jan 2025
    • Study completion date: Jan 2022 to Jan 2027
    v6
  3. Study sites: 7 to 6
    • Secondary endpoints: details revised at 1 of 1 entry
    v5
  4. Study sites: 8 to 7
    • Eligibility criteria expanded, about 90 words
    v4
  5. Study sites: 6 to 8
    • Start date: Jan 2017 to Jan 3, 2017
    • Eligibility criteria revised
    v3
  6. Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 0 to 6
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment
Trial Details
NCT Number NCT03024684
Lead Sponsor Chiayi Christian Hospital
Collaborators: E-DA Hospital, National Taiwan University Hospital, Taichung Veterans General Hospital, Mackay Memorial Hospital, Tainan Municipal Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital
Conditions
(from sponsor)		 HepatoCellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov